143 related articles for article (PubMed ID: 12605799)
1. [Thiazolidinediones: effect of the pioglitazone on hyperglycemia, dyslipidemia and cardiovascular risk].
Tan MH
Rev Clin Esp; 2003 Jan; 203(1):33-40. PubMed ID: 12605799
[No Abstract] [Full Text] [Related]
2. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Nakamura T; Ushiyama C; Osada S; Shimada N; Ebihara I; Koide H
Ren Fail; 2001 Nov; 23(6):863-4. PubMed ID: 11777327
[No Abstract] [Full Text] [Related]
3. LDL cholesterol and troglitazone therapy.
Howard BV; Howard WJ
Diabetes Care; 1998 Dec; 21(12):2201-3. PubMed ID: 9839127
[No Abstract] [Full Text] [Related]
4. Cardiovascular risk reduction with pioglitazone.
Cardiovasc J S Afr; 2002; 13(4):218. PubMed ID: 12402932
[No Abstract] [Full Text] [Related]
5. Postprandial dysmetabolism and the heart.
Garber AJ
Heart Fail Clin; 2012 Oct; 8(4):563-73. PubMed ID: 22999240
[TBL] [Abstract][Full Text] [Related]
6. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
7. Natural antioxidant compounds in risk factors for CVD.
Kaliora AC; Dedoussis GV
Pharmacol Res; 2007 Aug; 56(2):99-109. PubMed ID: 17572098
[TBL] [Abstract][Full Text] [Related]
8. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
[TBL] [Abstract][Full Text] [Related]
9. Effects of thiazolidinediones on cardiovascular risk factors.
Gouda BP; Asnani S; Fonseca VA
Compr Ther; 2002; 28(4):200-6. PubMed ID: 12506489
[TBL] [Abstract][Full Text] [Related]
10. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Lebovitz HE
Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
[TBL] [Abstract][Full Text] [Related]
11. The hypoglycemic effect of ciglitazone in obese, hyperglycemic animal models.
Chang AY; Wyse BM
Prog Clin Biol Res; 1988; 265():177-92. PubMed ID: 3043443
[No Abstract] [Full Text] [Related]
12. [Cardiovascular effects of the thiazolidinedione troglitazone].
Yamada K; Kuzuya H; Nakano T
Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572
[TBL] [Abstract][Full Text] [Related]
13. Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs).
Goldstein BJ
Clin Ther; 2002 Aug; 24(8):1358-60; author reply 1360-2. PubMed ID: 12240785
[No Abstract] [Full Text] [Related]
14. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
[TBL] [Abstract][Full Text] [Related]
15. Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
Zimmet P
Trends Cardiovasc Med; 2002 Nov; 12(8):354-62. PubMed ID: 12536122
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of troglitazone.
Umland EM; Romanelli AM
Ann Pharmacother; 1999 Feb; 33(2):229-32. PubMed ID: 10084419
[No Abstract] [Full Text] [Related]
17. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Mudaliar S; Henry RR
Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
[TBL] [Abstract][Full Text] [Related]
18. FDA approves pioglitazone for diabetes.
Miller JL
Am J Health Syst Pharm; 1999 Sep; 56(17):1698. PubMed ID: 10512494
[No Abstract] [Full Text] [Related]
19. Improvement of asthma after administration of pioglitazone.
Hashimoto Y; Nakahara K
Diabetes Care; 2002 Feb; 25(2):401. PubMed ID: 11815521
[No Abstract] [Full Text] [Related]
20. New drug overview. Pioglitazone hydrochloride.
Am J Health Syst Pharm; 2000 Jan; 57(2):124-5. PubMed ID: 10688239
[No Abstract] [Full Text] [Related]
[Next] [New Search]
